Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Godavari DrugsBOM:530317 -0.49%54 Return-on-Tangible-Equity is 6.81% as of Mar. 2026, which is 39% below its 10-year median of 11.23. GuruFocus rates BOM:530317 with a GF Score™ of 54/100 and a GF Value™ of ₹72.35 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 895 Drug Manufacturers companies, Godavari Drugs ranks worse than 50.28% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Godavari Drugs's annualized net income for the quarter that ended in Mar. 2026 was ₹52 Mil. Godavari Drugs's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹758 Mil. Therefore, Godavari Drugs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 6.81%.
The historical rank and industry rank for Godavari Drugs's Return-on-Tangible-Equity or its related term are showing as below:
BOM:530317'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.99 Med: 11.23 Max: 19.42
Current: 7.46
During the past 13 years, Godavari Drugs's highest Return-on-Tangible-Equity was 19.42%. The lowest was 4.99%. And the median was 11.23%.
BOM:530317's Return-on-Tangible-Equity is ranked worse than 50.28% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.61
vs BOM:530317: 7.46
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Godavari Drugs Return-on-Tangible-Equity Related Terms
Godavari Drugs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Godavari Drugs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530317 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Godavari Drugs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Godavari Drugs Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Godavari Drugs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Godavari Drugs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.81% mean?
Godavari Drugs (BOM:530317) has a Return-on-Tangible-Equity of 6.81% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Godavari Drugs and its competitors. This is 39% below median its historical median of 11.23. Over the past decade, Godavari Drugs' Return-on-Tangible-Equity has ranged from 4.99 to 19.42. According to the industry distribution chart, Godavari Drugs ranks #450 out of 895 companies in the Drug Manufacturers industry, placing it in the top 50.3%.
Is Godavari Drugs' Return-on-Tangible-Equity too high?
Godavari Drugs' current Return-on-Tangible-Equity of 6.81% is 39% below median its 10-year median of 11.23. Over the past 10 years, this metric has ranged from a low of 4.99 to a high of 19.42. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.61. Godavari Drugs' value of 6.81% is 10.5% below this industry median. Based on the distribution chart, Godavari Drugs ranks #450 out of 895 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Godavari Drugs has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Godavari Drugs ranks #450 out of 895 companies for Return-on-Tangible-Equity. This places Godavari Drugs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.61. Godavari Drugs' value of 6.81% is 10.5% below this benchmark. Historically, Godavari Drugs' own Return-on-Tangible-Equity has ranged from 4.99 to 19.42 over the past decade. While the company's 10-year median is 11.23 vs. the industry median of 7.61, Godavari Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.61, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Godavari Drugs's current Return-on-Tangible-Equity of 6.81% is 10.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Godavari Drugs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Godavari Drugs's current Return-on-Tangible-Equity is 6.81%, which is 39% below median its own 10-year median of 11.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹72.35, compared to a current price of ₹102.50 — trading 41.7% above its estimated fair value. The current Return-on-Tangible-Equity is 6.81%, which is 39% below median its 10-year median of 11.23 and 10.5% below the Drug Manufacturers industry median of 7.61. Godavari Drugs' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current Return-on-Tangible-Equity is 6.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Godavari Drugs (BOM:530317) Overvalued in 2026?
Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued.
The current stock price of ₹102.50 is trading 41.7% above its estimated GF Value™ of ₹72.35.
GuruFocus considers Godavari Drugs to be Significantly Overvalued.
Key valuation signals for BOM:530317:
Return-on-Tangible-Equity: 6.81% (39% below median its 10-year median of 11.23)
GF Value™: ₹72.35 vs. price of ₹102.50 (41.7% above fair value)
Industry Position: 10.5% below the Drug Manufacturers median (#450 of 895)
No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
54GF Score
Get the complete analysis for BOM:530317
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530317 has been successfully added to your 
